CSL (ASX:CSL) said it is planning for CSL Seqirus to be demerged as an ASX-listed global influenza vaccine firm before the end of fiscal year 2026, according to a Tuesday Australian bourse filing.

CSL Seqirus will be chaired by its former president Gordon Naylor.

Both entities will have access to funding to pursue distinct growth strategies, per the filing. The demerger will be subject to third-party consents and regulatory approvals, with CSL also conducting a voluntary shareholder vote.

The firm also plans to reduce its headcount by 15% as part of a cost-cutting initiative. It will adopt a new portfolio development and commercialization operating model, which will integrate the research and development, business development, and commercial teams. CSL Behring and CSL Vifor will also combine medical and commercial functions.

In August, the firm closed 22 "underperforming" centers, representing 7% of CSL Plasma's US footprint.